Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Do we know who is presenting on Monday in addition to FM & DW?
Just spent a couple of hours digesting this " FAP as a target, bench to bedside, narative review".
Published 19/8/21.
It brings together some 130 published papers on the use of FAP as a target for solid tumor therapies.
It specifically refers to doxrubicin on p14 and its possible use.
It also helps to put the latest Avacta presentation in context and confirms they are on the right track and it seems ahead of the pack.
Not sure if this has been linked before, but first time i have seen it.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416977/
Had a site visit late last night, full night shift working. Plenty of cars in the car park.
All very positive.
Nice upfront and large multiple milestone payments and royalty %. CanSEEK.
License agreement with Avacta Lifesciences Limited (“AVACTA”) for Tumor Microenvironment Targeting Technology In December 2020, we entered into an agreement with AVACTA (“AVACTA Agreement”). Under the AVACTA Agreement, we became a sublicensee of AVACTA’s license for using the intellectual property of developing and marketing radiopharmaceutical agents. Under this agreement, we obtained an exclusive license of AVACTA’s patent rights to use, develop, manufacture and commercialize any FAP-activated PSMA targeted radiopharmaceutical and a non-exclusive license of AVACTA’s patent rights for other FAP-activated radiopharmaceuticals arising from the licensed technology. We will pay during 2021 an upfront payment of $1.0 million for the initial license fee, $250,000 of which has already been paid and the remaining payments are due upon preclinical milestones. We are further obligated to make aggregate milestone payments to AVACTA of up to $4,500,000, upon the achievement of specified development milestones for our first product and up to $3,000,000 each for any license products upon reaching the specified development milestone. In addition, we are obligated to pay a milestone payment of $5,000,000 for each product for the regulatory milestone of being approved in specified territories. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are also obligated to pay a single digit percentage royalty (subject to a reduction on certain conditions) related to the annual net sales by us, our affiliates or our sublicensees for each licensed product or license process and a single digit percentage royalty on a specified product arising out of the patents. The royalty rate will be reduced by 50% for net sales occurring in the United States if there is no valid claim at the time of sale. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are responsible for all costs and expenses incurred related to the development, manufacture, regulatory approval and commercialization of all licensed products. In January 2021, we paid $250,000 of the initial license fee.
Worth a read:
http://affyxell.com/technology/tech.php?PHPSESSID=2e7f56008fda1be49aada1322fd66c71
Understood that AVCT own ~ 17%? of AffyXell + % of sales
AffyXell Platform
Novel Cell & Gene Therapy Platform for Immune-mediated Diseases
'AffyXell' , developed by Afficell Therapeutics, is a next-generation cell/gene therapy that introduces the Affimer® gene into DW-MSC, which has the advantage of not losing the characteristics of stem cells for a long time . 'AffyXell' maintains the immune/inflammation control function of stem cells as it is, and it is expected to be more effective than stem cells developed so far by further strengthening the immune/inflammatory control function with Affimer®.
In addition, Affimer® is a substance that acts on a specific protein and has the advantage of clearly explaining the mechanism of action for the therapeutic effect of AffyXell .
AffyXell is based on DW-MSC , so it can be used for multiple people (homeopathic drug) and can be developed as a cryoform ready -made product that can be administered to patients without any manipulation at the hospital. Hopefully it will be a cure
Great work Marik & RAH thank you for sharing & for Sportstrader for linking.
It is great first indications - we can all sleep well this weekend.
EGTP - totally agree with yoir post.
A definate inflection point on the Share price.
Nice gains yesterday when the general world markets were taking a battering.
Looking forward to a rich news flow from here on.
GLA
Today's RNS and the positive data to date, may give confidence to Point for them to press on with their development work. As they stated they were awaiting data from this trial.
From Points IPO doc.
”Preclinical Data and Next Steps. (p92)
We are currently evaluating development plans to advance our tumor microenvironment targeting technology prodrug platform, and plan to assess its application to PMSA targeting ligands. Avacta Life Sciences has recently received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase 1 study of its lead pre | CISIONTM prodrug, AVA6000 pro-doxorubicin, and we eagerly await the clinical data from their program as well as it may help us inform our own development plans"
Wonder if Avacta will be looking to do this?
Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. Fast Track designation must be requested by the drug company.
Lools to be a good USA cancer hospital to do an AVA6000 trial at!!
https://www.mskcc.org/news-releases/msk-named-one-best-hospitals-cancer-care-u-s-news-world-report-31st-year-row
All part of the Astbury centre leeds
https://twitter.com/LeedsAlumni/status/1487094999758090247?s=20&t=VxiDRsB3WD-3hdsLn5i6kQ
I especially like the potential to overcome antibiotic resistant bacterial infections.
https://astbury.leeds.ac.uk/people/dr-darren-tomlinson/
May or may not need updating ?
POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
From the interim results :-
"Nevertheless, the Board currently anticipates full year underlying trading will be slightly ahead of expectations, with the one-off benefits of the Covid-related grant income and contribution from discontinued operations incremental to this."
I am still thinking that turnover could reach the 130m+ for this year, with an increase to 140 m + next, given continued fair trading conditions.
A nice and steady recovery being made, director buys are a great confimation of this.
2 - 3 weeks would seem appropriate in this instance, ( share buy pre a general trading update).
Given that they have alteady RNS'd that they are ahead of expextations.
So any time in the next week or 2 would be ok for an update.
Point have stated that they are keen to view data from the AVA6000 trial before pushing on tbe can seek programme.
This is a great indicator that things are progressing well.
Full steam ahead on multiple fronts...
GLA
Latrobe facility seeking new employees for expansion again.
https://www.facebook.com/108547460596320/posts/635382187912842/?sfnsn=scwspmo
Carclo is seeking Team Members for Inspector Packers positions at the our Latrobe facility. The Day shift is 7 AM to 7 PM and the Night shift is 7 PM to 7 AM. (12-hour shifts on a 2-2-3 schedule). Previous experience is a plus, but we will train you!
Basic duties are:
Perform careful visual inspections to assure product quality.
Package product as directed; label and prepare product to customer standards.
Understand and operate all equipment in the work station.
Lift and move objects up to 50 pounds.
Stand and walk for an extended period of time
Follow procedures for proper startup and shutdown of equipment.
What are the benefits?
Competitive hourly wage
Outstanding benefits package that includes medical/dental/vision, paid vacation, paid holidays, and a 401(k) plan
Opportunity for advancement with accredited apprenticeship programs
Company sponsored events
Retention bonus
Carclo Technical Plastics is an EOE/ADA
In previous years Avacta have issued a trading update in midish January, providing shareholders with useful performance and outlook guidance.
Hopefully this will be the case this year, or as per January last year 2 specific update RNS's.
So perhaps 2-3 weeks at most to wait.
Exciting times
GLA
In the past we have been provided with a trading update any time from end of Dec to early Feb.
Hopefully the new management will give the market some trading guidance in the next couple of weeks, similar to the useful summer update.